HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and EPB41L3 methylation classifier

Cancer Biomarkers

Volumn 15, Issue 5, 2015, Pages 669-675

  Brentnall, Adam R ^a   Vasiljevic, Natasa ^a   Scibior Bentkowska, Dorota ^a   Cadman, Louise ^a   Austin, Janet ^a   Cuzick, Jack ^a   Lorincz, Attila T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cervical intraepithelial neoplasia; DNA methylation; early detection of cancer; human papillomavirus 33; human papillomavirus DNA tests; uterine cervical neoplasms

Indexed keywords

EPB41L3 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER RISK; COLPOSCOPY; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; DNA METHYLATION ASSAY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; MAJOR CLINICAL STUDY; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PRECANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; EARLY CANCER DIAGNOSIS; GENETICS; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; PREGNANCY; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

DNA METHYLATION; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 31; HUMANS; PAPILLOMAVIRIDAE; PREGNANCY; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84941282742     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150507     Document Type: Article

References (23)

1. A.R. Brentnall, N. Vasiljević, D. Scibior-Bentkowska, L. Cadman, J. Austin, A. Szarewski, J. Cuzick and A.T. Lorincz. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes, Int J Cancer 135 (2014), 1425-1432.
2. T.T. Cox, P.E. Castle, C.M. Behrens, A. Sharma, T.C. Wright, J. Cuzick and Athena HPV Study Group, Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study, American Journal of Obstetrics and Gynecology 208 (2013), 184.e1-184.e11.
3. J. Cuzick, L. Ho, G. Terry, M. Kleeman, M. Giddings, J. Austin, L. Cadman, L. Ashdown-Barr, M.J. Costa and A. Szarewski, Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions, Journal of Clinical Virology 60 (2014), 44-49.
4. J. Cuzick, A. Szarewski, G. Terry, L. Ho, A. Hanby, P. Maddox, M. Anderson, G. Kocjan, S.T. Steele and J. Guillebaud, Human papillomavirus testing in primary cervical screening, Lancel 345 (1995), 1533-1536.
5. J.J. Eijsink, A. Lendvai, V. Deregowski, H.G. Klip, G. Verpooten, L. Dehaspe, G.H. de Bock, H. Hollema, W. van Criekinge, E. Schuuring, A.G. van der Zee and G.B. Wisman, A four-gene methylation marker panel as triage test in highrisk human papillomavirus positive patients, Int J Cancer 130 (2012), 1861-1869.
6. A.T. Hesselink, D.A.M. Heideman, R.D.M. Steenbergen, M. Gök, F.J. van Kemenade, S.M. Wilting, J. Berkhof, C.J.L.M. Meijer and P.J.F. Snijders, Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage highrisk HPV-positive women for colposcopy, Int J Cancer 135 (2014), 880-886.
7. W.K. Huh, K.A. Ault, D. Chelmow, D.D. Davey, R.A. Goulart, F.A. Garcia, W.K. Kinney, S.S. Massad, E.J. Mayeaux, D. Saslow, M. Schiffman, N. Wentzensen, H.W. Lawson and M.H. Einstein, Use of primary High-Risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance, Obstetrics and Gynecology 136 (2015), 178-82.
8. S. Jain, T.K. Wojdacz and Y.-H.H. Su, Challenges for the application of DNA methylation biomarkers in molecular diagnostic testing for cancer, Expert Review of Molecular Diagnostics 13 (2013), 283-294.
9. H.-C.C. Lai, Y.-W.W. Lin, R.-L.L. Huang, M.-T.T. Chung, H.-C.C. Wang, Y.-P.P. Liao, P.-H.H. Su, Y.-L.L. Liu and M.-H.H. Yu, Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse, Cancer 116 (2010), 4266-4274.
10. A.T. Lorincz, Cancer diagnostic classifiers based on quantitative DNA methylation, Expert Review of Molecular Diagnostics 14 (2014), 293-305.
11. A.T. Lorincz, A.R. Brentnall, N. Vasiljević, D. Scibior-Bentkowska, A. Castanon, A. Fiander, N. Powell, A. Tristram, J. Cuzick and P. Sasieni, HPV16 l1 and l2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology, Int J Cancer 133 (2013), 637-644.
12. L. Mirabello, M. Schiffman, A. Ghosh, A.C. Rodriguez, N. Vasiljevic, N. Wentzensen, R. Herrero, A. Hildesheim, S. Wacholder, D. Scibior-Bentkowska, R.D. Burk and A.T. Lorincz, Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia, Int J Cancer 132 (2013), 1412-1422.
13. L. Mirabello, C. Sun, A. Ghosh, A.C. Rodriguez, M. Schiffman, N. Wentzensen, A. Hildesheim, R. Herrero, S. Wacholder, A. Lorincz and R.D. Burk, Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a costa rican population, Journal of the National Cancer Institute 104 (2012), 556-565.
14. R.M. Overmeer, J.A. Louwers, C.J. Meijer, F.J. van Kemenade, A.T. Hesselink, N. Fransen, S.M. Wilting, D.A. Heideman, R.H. Verheijen, A. Zaal, M.M. van Baal, J. Berkhof, P.J. Snijders and R.D. Steenbergen, Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women, Int J Cancer 129, 2218-2225.
15. J. Peto, C. Gilham, O. Fletcher and F.E. Matthews, The cervical cancer epidemic that screening has prevented in the UK, Lancet 364 (2004), 249-256.
16. R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2012, ISBN 3-900051-07-0.
17. A. Szarewski, L. Ambroisine, L. Cadman, J. Austin, L. Ho, G. Terry, S. Liddle, R. Dina, J. McCarthy, H. Buckley, C. Bergeron, P. Soutter, D. Lyons and J. Cuzick, Comparison of predictors for High-Grade cervical intraepithelial neoplasia in women with abnormal smears, Cancer Epidemiology Biomarkers & Prevention 17 (2008), 3033-3042.
18. A. Szarewski, D. Mesher, L. Cadman, J. Austin, L. Ashdown-Barr, L. Ho, G. Terry, S. Liddle, M. Young, M. Stoler, J. Mc-Carthy, C. Wright, C. Bergeron, W.P. Soutter, D. Lyons and J. Cuzick, A comparison of seven tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study, Journal of Clinical Microbiology 50 (2012), 1867-1873.
19. N. Vasiljević, D. Scibior-Bentkowska, A. Brentnall, J. Cuzick and A. Lorincz, A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers, Journal of Clinical Virology 59 (2014), 161-166.
20. V.M. Verhoef, D.A. Heideman, F.J. van Kemenade, L. Rozendaal, R.P. Bosgraaf, A.T. Hesselink, R.L. Bekkers, L.F. Massuger, R.D. Steenbergen, P.J. Snijders, J. Berkhof and C.J. Meijer, Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer, Gynecologic Oncology 135 (2014), 58-63.
21. T.C. Wright, M.H. Stoler, C.M. Behrens, A. Sharma, G. Zhang and T.L. Wright, Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test, Gynecologic Oncology 136 (2015), 189-197.
22. N. Vasiljević, D. Scibior-Bentkowska, A.R. Brentnall, J. Cuzick and A.T. Lorincz. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecologic Oncology 132 (2014), 709-714.
23. M.S. Pepe, K.F. Kerr, G. Longton and Z. Wang (2013). Testing for improvement in prediction model performance. Statist Med 32 (9), 1467-1482.